Business

Agreement aims to make Dyax’s hereditary angioedema drug available in China

Dyax Corp. of Burlington is partnering with CVie Therapeutics as part of plan to make its hereditary angioedema drug available in China, Hong Kong, and Macau.

The drug, Kalbitor, is currently marketed in United States for the treatment of acute attacks of hereditary angioedema, or HAE, in patients 16 years of age and older. According to Dyax’s website, HAE is a rare disease of the immune system, affecting an estimated 1 in 10,000 to 1 in 50,000 people around the world.

Advertisement

The agreement disclosed in Thursday’s press release calls for CVie Therapeutics to develop amd commercialize Kalbitor in geographies covered by the partnership.

In turn, Dyax is in line to receive an upfront payment, and the company is also eligible to receive future development, regulatory and sales milestones as well as royalties on net product sales. The amounts of those payments were not included in the press release.

‘‘Our partnership with CVie is another milestone in our effort to expand the global development and commercialization of Kalbitor, and to reach HAE patients in need around the world,” Gustav Christensen, president and chief executive of Dyax, said in a statement. “If approved, Kalbitor would become the first novel therapy available for HAE in China, where presently only steroids are used.”

Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.